@article{oai:nagasaki-u.repo.nii.ac.jp:00027716,
 author = {Noda, Keisuke and Tominaga, Tetsuro and Nonaka, Takashi and Araki, Masato and Sumida, Yorihisa and Takeshita, Hiroaki and Fukuoka, Hidetoshi and To, Kazuo and Tanaka, Kenji and Sawai, Terumitsu and Nagayasu, Takeshi},
 issue = {1},
 journal = {Acta medica Nagasakiensia},
 month = {Oct},
 note = {Purpose: The impact of neoadjuvant chemotherapy for locally advanced colorectal cancer has not yet been investigated; thus, this study aimed to examine the safety, feasibility, and oncological effects of neoadjuvant chemotherapy for locally advanced colorectal cancer.
Methods: In this multicenter study, we retrospectively reviewed the data of 83 locally advanced colorectal cancer patients (cT3/4 or N1/2) who received neoadjuvant chemotherapy followed by radical resection between April 2016 and September 2020. The NAC regimens were FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin), XELOX (capecitabine and oxaliplatin), or SOX (S-1 and oxaliplatin). We evaluated the pathological responses as well as the short- and long-term outcomes.
Results: A pathological complete response was achieved in 4 patients (4.8%). Tumor down-staging and nodal down-staging were achieved in 57 (68.7%) and 49 (59.0%) patients, respectively. One patient (1.2%) experienced progressive disease. Postoperative complications occurred in 21 patients (25.3%). Multivariate analysis revealed that the pathological N positive status (p = 0.015; odds ratio, 4.458; 95% confidence interval, 1.331 to 7.9300) was an independent predictive factor for relapse-free survival.
Conclusion: Neoadjuvant chemotherapy for colorectal cancer could achieve good tumor control and down-staging without increasing the rate of complications. Appropriate preoperative treatment that can reduce the rate of the pathological nodepositive disease may improve oncological outcomes., Acta medica Nagasakiensia, 66(1), pp.13-19; 2022},
 pages = {13--19},
 title = {Neoadjuvant chemotherapy in locally advanced colorectal cancer: a Japanese multicenter study},
 volume = {66},
 year = {2022}
}